Evaluation of cancer chemopreventive agents using clones derived from a human prostate cancer cell line.
The successful use of clonal selection through fluctuation analysis of human cancer cells as a means for studying tumor progression has been previously reported. Three clones derived from a parental population of human prostate cancer (LNCaP) cells were selected based on proliferation, hormone sensitivity and anchorage-independent growth. The effects of five potential cancer preventive agents were evaluated using cell proliferation, anchorage-independent growth and apoptosis as end-points. Clone 21 cells, which represent a presumptive normal phenotype, were generally more sensitive than Clone 17 and Clone 6 cells, which represent a more malignant phenotype, to fluasterone, 7beta-HF, L-selenomethionine and troglitazone in assays for proliferation and/or apoptosis. The results confirm the efficacy of the above agents as cancer chemopreventive agents and support our contention that clonal selection of established human cancer cells provides a model to study the efficacy of chemopreventive agents.